Replimune Group (REPL) Revenue & Revenue Breakdown
Replimune Group Revenue Highlights
00
Replimune Group Revenue by Period
Replimune Group Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-03-31 | - | - |
Replimune Group generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Replimune Group Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | -100.00% |
| 2025-03-31 | $1.47M | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $4.04M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Replimune Group generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Replimune Group Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $263.40M | $41.90M |
| DNA | Ginkgo Bioworks | $227.04M | $49.60M |
| IOVA | Iovance Biotherapeutics | $164.07M | $67.45M |
| VALN | Valneva SE | $153.70M | $32.75M |
| VIR | Vir Bio | $74.20M | $240.00K |
| MGTX | MeiraGTx | $33.28M | $3.69M |
| PRME | Prime Medicine | $2.98M | $1.23M |
| REPL | Replimune Group | - | - |
| ATXS | Astria Therapeutics | - | $706.00K |
| MBX | MBX Biosciences | - | - |
| AVBP | ArriVent BioPharma | - | - |